Ligand Pharmaceuticals has been granted a patent for compounds and methods involving imidazole-fused heterocycle amines. The disclosed embodiments include compounds useful for treating leukemia and hematopoietic disorders. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ligand Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11858938B2) discloses a compound of Formula (III) along with various specific embodiments and variations. The compound described in the claims includes different substituents such as hydrogen, heterocyclylalkyl groups like pyrrolidyl-CH2-, piperidinyl-CH2-, and morpholine-CH2-, as well as heteroaryl groups like pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, and pyrazolyl. The patent also covers pharmaceutical compositions containing the compound of claim 1 or its derivatives in combination with pharmaceutically acceptable carriers, diluents, or excipients.

Furthermore, the patent claims encompass different configurations and substitutions for the compound, including variations in the R1, R2, R3, R4a, R5a, and R5b groups. These variations range from hydrogen atoms to specific heterocyclic or heteroaryl groups, providing a broad scope for potential applications and formulations. The pharmaceutical composition described in the claims offers a versatile platform for developing new drugs or treatments based on the disclosed compound and its derivatives, highlighting the potential for innovation and further research in the field of pharmaceutical chemistry.

To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies